Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2916 in Advanced Malignant Tumors
NCT05213767Phase 1Unknown
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2916 in cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 52 weeks, Dose Limited Toxicity at 52 weeks and 1 more. Status: unknown.
02
Drugs
TQB2916
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05213767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213767.